S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
TSE:MDP

Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

C$1.80
+0.01 (+0.56%)
(As of 02/28/2024 ET)
Today's Range
C$1.79
C$1.87
50-Day Range
C$1.64
C$3.12
52-Week Range
C$1.12
C$3.53
Volume
53,887 shs
Average Volume
64,715 shs
Market Capitalization
C$44.03 million
P/E Ratio
4.62
Dividend Yield
N/A
Price Target
N/A

MDP stock logo

About Medexus Pharmaceuticals Stock (TSE:MDP)

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

MDP Stock Price History

MDP Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
2/28/2024
Next Earnings (Estimated)
6/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
98
Year Founded
N/A

Profitability

Net Income
C$5.88 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$115.72 million
Book Value
C$1.21 per share

Miscellaneous

Free Float
N/A
Market Cap
C$43.78 million
Optionable
Not Optionable
Beta
1.85
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Kenneth d'Entremont
    CEO & Director
  • Mr. Marcel Konrad (Age 48)
    Chief Financial Officer
    Comp: $790.32k
  • Mr. Ian C. Wildgoose Brown
    General Counsel & Corporate Secretary
  • Ms. Tina Byers CFA
    Executive of Investor Relations
  • Mr. Bill Poncy
    Senior Vice President of Commercial Operations - United States
  • Mr. Brian Peters
    Vice President of Sales & Marketing - United States














MDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medexus Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDP shares.
View MDP analyst ratings
or view top-rated stocks.

How have MDP shares performed in 2024?

Medexus Pharmaceuticals' stock was trading at C$2.47 at the beginning of the year. Since then, MDP stock has decreased by 27.1% and is now trading at C$1.80.
View the best growth stocks for 2024 here
.

When is Medexus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 19th 2024.
View our MDP earnings forecast
.

How were Medexus Pharmaceuticals' earnings last quarter?

Medexus Pharmaceuticals Inc. (TSE:MDP) released its earnings results on Wednesday, February, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by $0.13. The business had revenue of $34.33 million for the quarter, compared to analyst estimates of $42.33 million. Medexus Pharmaceuticals had a trailing twelve-month return on equity of 26.14% and a net margin of 5.08%.

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:MDP) was last updated on 2/28/2024 by MarketBeat.com Staff